Patents Examined by Timothy R Rozof
  • Patent number: 10477864
    Abstract: Compounds of the formula (I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, in particular fungi.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: November 19, 2019
    Assignee: Syngenta Participations AG
    Inventors: Matthias Weiss, Farhan Bou Hamdan, Laura Quaranta
  • Patent number: 10472349
    Abstract: A mesylate salt of the compound of formula (I), the preparation method thereof, a pharmaceutical composition containing said salt and the use of said salt in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancers, in mammal, in particular human. The mesylate salt of the compound of formula (I) has a high bioavailability in animal, and can remarkably inhibit the growth of transplanted tumors in animal and show a good safety.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 12, 2019
    Assignee: SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECH CO
    Inventors: Huibing Luo, Huayong Zhou
  • Patent number: 10464903
    Abstract: The present invention relates (i) to a process for the preparation of quinolin-2-yl-phenylamine derivatives of formula (I) without a metal catalyst, and (ii) to soluble mineral acid or sulfonic acid salts of (8-chloro-quinolin-2-yl)-(4-trifluoromethoxyphenyl)-amine.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 5, 2019
    Assignee: RATIOPHARM GMBH
    Inventors: Sebastian Rabe, Wolfgang Albrecht
  • Patent number: 10464915
    Abstract: Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(?-D-glucopyranose-1-yl)-4?-ethyoxyldiphenylmethane and a preparation method therefor, and a pharmaceutical composition containing a therapeutically effective amount of the crystal form and the use thereof in treating type II diabetes.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: November 5, 2019
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Xiang Li, Lei He, Jun Yu, Jinjia Wang, Zuyin Du
  • Patent number: 10457640
    Abstract: Provided herein are synthetic methods for the preparation of EZH2 inhibitors.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: October 29, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Rishi G. Vaswani, Michael Charles Hewitt
  • Patent number: 10457670
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 29, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Patent number: 10450272
    Abstract: The present invention provides a homogeneous process for hydrodehalogenating a halo-substituted C3-C20 heteroaryl starting material to form a non-halogenated C3-C20 heteroaryl product and/or a halo-substituted C3-C20 heteroaryl product, wherein the halo-substituted C3-C20 heteroaryl product has at least one less halogen substituents than the halo-substituted C3-C20 heteroaryl starting material, the process comprising the step of hydrogenating the halo-substituted C3-C20 heteroaryl starting material in the presence of a rhodium or ruthenium complex, molecular hydrogen, a base and a solvent, wherein the process is carried out in a monophasic solvent system and the molar ratio of base to each halogen substituent to be removed is at least 1:1.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: October 22, 2019
    Assignee: Johnson Matthey Public Limited Company
    Inventor: Danny Lee Mortimer
  • Patent number: 10450251
    Abstract: There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R1 is hydrogen or a protecting group; said method comprising oxidizing verbenone and optical isomers thereof.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: October 22, 2019
    Assignee: E-THERAPEUTICS PLC
    Inventors: Vijaya Bhasker Gondi, James Thomson Loch, III, Nicholas John Holman, Steven James Collier
  • Patent number: 10442799
    Abstract: In recognition of the unmet need to develop novel therapeutic agents, the present invention discloses a novel class of heterocycles as dual inhibitors of BRD4 and class I PI3Ks. The compounds claimed herein could be used alone or in combination therapies for the effective treatment of a wide range of age-related diseases, including cancer. The present invention also provides methods for preparing compounds of the invention thereto.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: October 15, 2019
    Inventor: Fuqiang Ruan
  • Patent number: 10434186
    Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: October 8, 2019
    Assignee: LUMIPHORE, INC.
    Inventors: Nathaniel G. Butlin, Darren Magda, Jide Xu
  • Patent number: 10435563
    Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, L1, L2, L3, L4, L5, L6, M1, M2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: October 8, 2019
    Assignees: Sony Corporation, Sony Corporation of America
    Inventors: Tracy Matray, Hesham Sherif, C. Frederick Battrell
  • Patent number: 10435411
    Abstract: In crop production in the fields of agriculture, horticulture and the like, the damage caused by insect pests etc. is still immense, and insect pests resistant to existing insecticides have emerged. The present invention has been made in view of such circumstances, and an object of the present invention is to develop and provide a novel agricultural and horticultural insecticide. The present invention provides an oxime group-containing quinoline compound represented by the general formula (1): (wherein R1 is a haloalkyl group, R2 is a hydrogen atom or an alkyl group, R3 is a haloalkyl group or an alkylthio alkyl group, A is an N-methyl group, A1 is a nitrogen atom, A2 is CH, m is 2, and n is 1), or a salt thereof; an agricultural and horticultural insecticide comprising the compound or a salt thereof as an active ingredient; and a method for using the insecticide.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 8, 2019
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Naoto Shimizu, Ikki Yonemura, Yusuke Sano, Akiyuki Suwa, Shunpei Fujie
  • Patent number: 10435381
    Abstract: The present invention is related to a process for preparing propylene oxide, comprising (i) providing a stream comprising propene, hydrogen peroxide or a source of hydrogen peroxide, water, and an organic solvent; (ii) passing the liquid feed stream provided in (i) into an epoxidation zone comprising an epoxidation catalyst comprising a titanium zeolite, and subjecting the liquid feed stream to epoxidation reaction conditions in the epoxidation zone, obtaining a reaction mixture comprising propene, propylene oxide, water, and the organic solvent; (iii) removing an effluent stream from the epoxidation zone, the effluent stream comprising propylene oxide, water, organic solvent, and propene; (iv) separating propene from the effluent stream by distillation, comprising (iv.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: October 8, 2019
    Assignees: BASF SE, Dow Global Technologies LLC
    Inventors: Joaquim Henrique Teles, Marvin Kramp, Christian Mueller, Nicolai Tonio Woerz, Bernd Metzen, Tobias Keller, Dominic Riedel, Heiner Schelling, Markus Weber, Daniel Urbanczyk, Andrei-Nicolae Parvulescu, Ulrike Wegerle, Ulrich Mueller, Meinolf Weidenbach, Werner J. Witzl, Karsten Luecke
  • Patent number: 10435384
    Abstract: A method for extracting herbacetin from plants of Rhodiola L., comprising the following steps: 1) performing an extracting process for the pulverized medical Rhodiola L. with an extracting solvent, and condensing to obtain an extract; 2) performing a leaching process for the extract and performing an acid hydrolysis for the extracted aqueous layer; 3) performing a leaching process for the solution after the acid hydrolysis with an organic solvent, combining the organic layer and concentrating under reduced pressure to obtain a herbacetin extract; 4) treating the herbacetin extract through polyamide column chromatography, collecting the outflow containing herbacetin and drying through condensation to obtain a crude herbacetin product; 5) treating the crude herbacetin product through reverse-phase silica-gel column chromatography, collecting the outflow containing herbacetin, drying through condensation and recrystallizing to obtain a pure herbacetin product.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 8, 2019
    Assignee: TAIZHOU DANDING BIOTECHNOLOGY CO., LTD.
    Inventors: Zhengbing Gu, Jie Zhang, Yuehong Tao, Cheng Zeng, Lili Xu
  • Patent number: 10414745
    Abstract: The present invention relates to compounds of general formula (I) wherein R1-R8 take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and/or prophylaxis of cancer.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: September 17, 2019
    Assignee: FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA
    Inventors: Nuria De Pedro Montejo, Victor Gonzalez Menendez, Gloria Crespo Sueiro, Ignacio Perez-Victoria Moreno De Barreda, Bastien Cautain, Maria Francisca Vicente Perez, Jose Fernando Reyes Benitez, Olga Genilloud Rodriguez, Carmen Grinan Lison, Juan Antonio Marchal Corrales
  • Patent number: 10414746
    Abstract: A method and an intermediate for preparing a tulathromycin. The method includes the following step: in an organic solvent, subjecting a compound represented by formula (II) and an n-propylamine to a ring-opening addition shown below to obtain a tulathromycin represented by formula (I), wherein the organic solvent is a 1,2-propandiol. Tulathromycin obtained using the method has a high purity, with an HPLC purity being 95% and above, and up to 99% and above, satisfying a required purity for preparing a tulathromycin as a pharmaceutical formulation. The method has a high yield, is simple to operate, and is more suitable for industrial production.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: September 17, 2019
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Mingxing Yin, Dongdong Wu, Weijiang Wen
  • Patent number: 10413537
    Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: September 17, 2019
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Gopi Kumar Mittapalli
  • Patent number: 10407402
    Abstract: A method of forming a chalcogenophene compound of formula (I) includes reacting a compound of formula (II) with a chalcogenide salt in presence of a proton source. Y is O, S, Se, Te or Po. R1 is hydrogen, deuterium, an aliphatic, heteroaromatic, or aromatic group, or a precursor of a leaving group Z whose conjugate acid (HZ) has pKa less than 30. R2 is hydrogen, deuterium, or an aliphatic, heteroaromatic, or aromatic group. R1 and R2 may be the same or different, and may joint together to form a saturated or unsaturated, heteroalicyclic or alicyclic ring. R3 is, for example, alkyl, aryl, heteroaryl, organosilyl, organotin, or organogermyl. R3? is the same as R3 or is hydrogen. X is a precursor of a leaving group X whose conjugate acid (HX) has a pKa of less than 30.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: September 10, 2019
    Assignee: National Tsing Hua University
    Inventors: Chien-Chung Han, Vamsi Krishna Karapala
  • Patent number: 10406140
    Abstract: Provided is a compound which is useful as an AMPK activator, represented by formula: wherein the symbols are defined in the specification.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 10, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yuusuke Tamura, Toshihiro Wada
  • Patent number: 10407404
    Abstract: A crystalline form of 2,2-difluoro-N-[(1R,2S)-3-methyl-1-{[1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1H-indazol-5-yl]oxy}-1-phenylbutan-2-yl]propanamide (form C), pharmaceutical compositions containing it and its use in therapy.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: September 10, 2019
    Assignee: ASTRAZENECA AB
    Inventor: Chaoyi Deng